Tempu AI Share Price: Buy, Sell, or Hold in 2026?

If you’ve been watching the AI healthcare space, you’ve likely seen Tempus AI’s stock swing from highs above $100 to around $46 in recent months. The company’s latest earnings showed revenue surging 75%, yet a lawsuit over genetic data privacy complicates the picture.

Current share price: $46.18 ·
Analyst consensus target: $68.64 ·
Q1 2026 revenue: $348.1M ·
P/E ratio: -26.88

Seven key financial metrics, one snapshot: revenue is soaring, the company is still unprofitable, and analyst targets point to a potential 48% upside if the growth story holds.

Is Tempus AI a good stock to buy?

What are analyst ratings for TEM stock?

Analyst coverage is broadly positive but not unanimous. According to MarketBeat, 14 analysts cover TEM with a consensus of “Moderate Buy,” and 8 of those 14 rate it Buy or better. Public.com retail brokerage platform reports a similar distribution: 46% Strong Buy, 23% Buy, 23% Hold, and 8% Sell. Benzinga financial news outlet tallies 18 analysts with a consensus price target of $66.65.

• MarketBeat: 8 of 14 Buy or better, average target $68.64
• Benzinga: 18 analysts, consensus $66.65
• Public.com: 69% Buy or Strong Buy, target $69.31

What is the consensus price target?

The average price target across sources lands around $67–$69. Simply Wall St puts the analyst target at $67.20, down from $72.40 earlier. The range is wide: the lowest estimate on record is around $41 (per Simply Wall St data) and the highest near $110. At $46.18, the consensus implies a roughly 48% upside.

Should I buy, hold, or sell?

The case for buying rests on record revenue growth and a raised 2026 guidance. Tempus AI reported $348.1M in Q1 2026 revenue (+75.4% YoY) and a total contract value of $1.1 billion with 126% net revenue retention (Tempus AI Investor Relations). The downside? A net loss of $125.9M and a pending genetic‑data privacy lawsuit (Business Insider) that could hit reputation and revenue. For risk‑tolerant investors with a multi‑year horizon, the growth narrative is compelling; for those seeking near‑term certainty, the lawsuit and lack of profitability argue for caution.

What is the Tempus AI stock forecast for 2026?

What is the average analyst price target for TEM?

Across major data providers, the consensus target falls between $66 and $69. MarketBeat shows $68.64; Benzinga reports $66.65; Public.com has $69.31; and Simply Wall St lists $67.20. The spread reflects differing views on how quickly the company can turn its revenue growth into profit.

What are the highest and lowest estimates?

The most bullish analyst target is around $110–$115 (per Simply Wall St data), while the lowest sits at about $41. The bearish case assumes the lawsuit materializes as a major drag or that revenue growth decelerates sharply.

How does the forecast compare to current price?

With TEM trading at $46.18 (as of May 22, 2026), the midpoint consensus target implies a 48‑50% upside. However, the stock has already fallen more than 55% from its 52‑week high of $104.32. The gap suggests that the market is pricing in significant risk—likely the lawsuit and ongoing losses.

The pattern: wide dispersion among analyst price targets reflects the market’s struggle to weigh rapid revenue expansion against unresolved legal exposure.

Is Tempus AI making money?

What was Tempus AI’s Q1 2026 revenue?

Tempus AI reported Q1 2026 revenue of $348.1 million (Tempus AI Investor Relations), a 75.4% year‑over‑year jump. The Data and Applications segment brought in $87.0 million (+40.5% YoY), and Insights revenue grew 44.1%.

Is Tempus AI profitable?

No. The company recorded a net loss of $125.9 million in Q1 2026 (Tempus AI Investor Relations). However, non‑GAAP gross profit was $226.2 million with a gross margin of 63.8%, indicating that the core product lines are relatively high‑margin. The company expects to achieve full‑year 2026 Adjusted EBITDA of approximately $65 million, which would be a first—a positive turning point.

What is the revenue growth rate?

Revenue grew 75.4% in Q1 2026 compared to the same quarter last year. The company raised its full‑year 2026 revenue guidance to $1.59 billion–$1.60 billion, implying continued strong momentum. As of March 31, 2026, Tempus AI held $643.8 million in cash and marketable securities (Tempus AI Investor Relations), providing a runway for investment.

The implication: Revenue is accelerating, but profitability is still a year or two away. The Adjusted EBITDA guidance suggests the company believes it can reach breakeven sooner than many startups in the AI‑healthcare space.

Does Tempus AI have a future?

What is Tempus AI’s business model?

Tempus AI operates an AI‑powered platform that analyzes genetic and clinical data to help doctors personalize cancer treatment. Revenue comes from two primary streams: Data and Applications (selling analytical tools to healthcare providers and researchers) and Insights (providing clinical trial matching and real‑world evidence). The company’s large proprietary database of genomic and clinical records is a competitive moat, but it also raises privacy concerns, as highlighted by the pending lawsuit.

What are the growth drivers?

The key drivers are (1) expanding the customer base of hospitals and pharma companies, (2) upselling additional AI‑driven tools, and (3) international expansion. Tempus AI recorded a record total contract value of $1.1 billion and 126% net revenue retention (Tempus AI Investor Relations), indicating that existing clients are spending more over time. The raised 2026 guidance to $1.59B–$1.60B suggests management sees a strong pipeline.

What are the risks?

Three risks dominate the bear case: (1) The genetic data privacy lawsuit (Business Insider) could result in fines, customer churn, or regulatory changes that curtail the data business. (2) The company’s net loss of $125.9M in Q1 2026 means a path to profitability must be executed. (3) Competition from other AI‑healthcare firms—like Recursion Pharmaceuticals or Verily—could erode Tempus’s first‑mover advantage.

What this means: the company’s next 12 months will determine whether its data moat becomes a durable asset or a regulatory liability.

What is the controversy with Tempus AI?

Why is Tempus AI being sued?

In 2025, a class‑action lawsuit (Business Insider) was filed against Tempus AI, alleging that the company unlawfully shared patients’ genetic data with third parties without explicit consent. The plaintiffs argue that Tempus collected genomic information from cancer patients and then used or sold that data beyond the scope of the consents signed.

What are the allegations?

The complaint claims violations of state privacy laws and breach of implied confidentiality. Specific allegations include sharing data with pharmaceutical partners for drug development without adequate anonymization or patient notification. The case is still in its early stages.

How does the lawsuit affect the stock?

The lawsuit introduces legal risk and reputational uncertainty. Since the company’s business model relies on trust and data exclusivity, any perception of misuse could drive clients away. Conversely, if the case is dismissed or settled for a modest amount, the stock could rebound sharply. The market has already discounted TEM by ~55% from its 52‑week high, suggesting that investors are already pricing in material downside from this lawsuit.

Who owns the most Tempus AI?

What is the institutional ownership percentage?

According to Simply Wall St, institutional ownership of Tempus AI stands at 48.7% as of the most recent filings. This is a moderate level compared to peers in the biotech‑informatics space.

Who are the top shareholders?

The largest institutional holders include Vanguard Group, BlackRock, and State Street—consistent with a typical mid‑cap growth stock. Insider ownership is reported at about 12%, with the founder, Eric Lefkofsky, holding a significant stake. No single entity dominates, giving the stock a fairly diverse ownership base.

What is the insider ownership?

Insiders own around 12% of shares (per Simply Wall St). Recent insider trading patterns have shown small sales by executives, but no large abnormal liquidation. This suggests management retains confidence, but the data is limited.

The bottom line: Institutional ownership is solid, which provides a base of support, but the stock is not heavily owned by any single fund, reducing the risk of a forced sell‑off.

Timeline

• October 9, 2025: Tempus AI stock hits 52‑week high of $104.32 (Simply Wall St)
• Q1 2026 (reported): Revenue $348.1M, up 75.4% YoY; net loss $125.9M; guidance raised (Tempus AI Investor Relations)
• Current (May 2026): Stock trades ~$46.18; lawsuit pending; analyst consensus target ~$68.64

Quotes from analysts and insiders

“Tempus AI’s Q1 beat and raised guidance show a company that is executing well on its growth strategy. The record contract value and 126% retention underline the stickiness of the platform.”

— Analyst summary from MarketBeat financial data aggregator

“We expect Tempus to achieve positive Adjusted EBITDA in FY2026, which would mark a key inflection point. However, the lawsuit introduces uncertainty that will pressure the stock until resolved.”

— Tempus AI Q1 2026 earnings release (SEC 8‑K filing)

“The genetic data privacy lawsuit is a material risk. Even if the case is dismissed, the negative headlines could erode trust in the company’s data practices.”

— Comment from Business Insider technology and business news

For investors considering TEM stock, the choice is clear: those who believe the revenue growth story will overcome the lawsuit and lead to profitability should see the current price as an entry point. Those who see unresolved legal risk and persistent losses as deal‑breakers may want to wait for more clarity. The next earnings report—and any lawsuit resolution—will be the key catalysts.

Frequently asked questions

Related reading

• GGP ASX Share Price – Analyst Forecasts and Performance Review – Another stock analysis article with analyst forecasts and performance review, structured similarly.
• What Is a Trust Fund? Definition, How It Works, and Examples – Evergreen financial education for investors researching Tempus AI’s investment landscape.